Logo image of ITOS

ITEOS THERAPEUTICS INC (ITOS) Stock Fundamental Analysis

USA - NASDAQ:ITOS - US46565G1040 - Common Stock

10.15 USD
+0.02 (+0.2%)
Last: 8/28/2025, 8:19:13 PM
10.17 USD
+0.02 (+0.2%)
After Hours: 8/28/2025, 8:19:13 PM
Fundamental Rating

3

Overall ITOS gets a fundamental rating of 3 out of 10. We evaluated ITOS against 538 industry peers in the Biotechnology industry. ITOS has a great financial health rating, but its profitability evaluates not so good. ITOS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ITOS had negative earnings in the past year.
ITOS had a negative operating cash flow in the past year.
In multiple years ITOS reported negative net income over the last 5 years.
In the past 5 years ITOS reported 4 times negative operating cash flow.
ITOS Yearly Net Income VS EBIT VS OCF VS FCFITOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

ITOS has a Return On Assets of -21.57%. This is in the better half of the industry: ITOS outperforms 75.83% of its industry peers.
ITOS's Return On Equity of -27.22% is fine compared to the rest of the industry. ITOS outperforms 79.52% of its industry peers.
Industry RankSector Rank
ROA -21.57%
ROE -27.22%
ROIC N/A
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ITOS Yearly ROA, ROE, ROICITOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

ITOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ITOS Yearly Profit, Operating, Gross MarginsITOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

7

2. Health

2.1 Basic Checks

ITOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ITOS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ITOS has been increased compared to 5 years ago.
There is no outstanding debt for ITOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ITOS Yearly Shares OutstandingITOS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ITOS Yearly Total Debt VS Total AssetsITOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 1.90 indicates that ITOS is not a great score, but indicates only limited risk for bankruptcy at the moment.
ITOS has a Altman-Z score of 1.90. This is in the better half of the industry: ITOS outperforms 66.79% of its industry peers.
ITOS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.9
ROIC/WACCN/A
WACC9.73%
ITOS Yearly LT Debt VS Equity VS FCFITOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

ITOS has a Current Ratio of 7.53. This indicates that ITOS is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.53, ITOS is doing good in the industry, outperforming 71.40% of the companies in the same industry.
A Quick Ratio of 7.53 indicates that ITOS has no problem at all paying its short term obligations.
With a decent Quick ratio value of 7.53, ITOS is doing good in the industry, outperforming 71.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.53
Quick Ratio 7.53
ITOS Yearly Current Assets VS Current LiabilitesITOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2

3. Growth

3.1 Past

The earnings per share for ITOS have decreased strongly by -43.67% in the last year.
ITOS shows a strong growth in Revenue. In the last year, the Revenue has grown by 177.89%.
The Revenue for ITOS have been decreasing by -53.35% on average. This is quite bad
EPS 1Y (TTM)-43.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-694.44%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, ITOS will show a small growth in Earnings Per Share. The EPS will grow by 3.35% on average per year.
ITOS is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y-7.51%
EPS Next 2Y17.23%
EPS Next 3Y13.13%
EPS Next 5Y3.35%
Revenue Next Year-100%
Revenue Next 2Y-61.63%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ITOS Yearly Revenue VS EstimatesITOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2026 2030 2031 2032 100M 200M 300M
ITOS Yearly EPS VS EstimatesITOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ITOS. In the last year negative earnings were reported.
Also next year ITOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ITOS Price Earnings VS Forward Price EarningsITOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITOS Per share dataITOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as ITOS's earnings are expected to grow with 13.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.23%
EPS Next 3Y13.13%

0

5. Dividend

5.1 Amount

ITOS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ITEOS THERAPEUTICS INC

NASDAQ:ITOS (8/28/2025, 8:19:13 PM)

After market: 10.17 +0.02 (+0.2%)

10.15

+0.02 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners104.81%
Inst Owner Change1.35%
Ins Owners1.18%
Ins Owner Change-15.43%
Market Cap448.73M
Analysts50
Price Target10.56 (4.04%)
Short Float %2.09%
Short Ratio0.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.81%
Min EPS beat(2)-39.15%
Max EPS beat(2)17.53%
EPS beat(4)2
Avg EPS beat(4)-8.08%
Min EPS beat(4)-39.15%
Max EPS beat(4)17.53%
EPS beat(8)6
Avg EPS beat(8)14.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.92%
PT rev (3m)-11.92%
EPS NQ rev (1m)-6.61%
EPS NQ rev (3m)-10.11%
EPS NY rev (1m)-10.29%
EPS NY rev (3m)-1.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.82
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-4.31
EYN/A
EPS(NY)-2.08
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0.79
BVpS11.17
TBVpS11.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.57%
ROE -27.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7.87%
ROA(5y)-2.39%
ROE(3y)-9.26%
ROE(5y)-0.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.87%
Cap/Sales 1.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.53
Quick Ratio 7.53
Altman-Z 1.9
F-Score3
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)204.25%
Cap/Depr(5y)178.55%
Cap/Sales(3y)9.83%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-694.44%
EPS Next Y-7.51%
EPS Next 2Y17.23%
EPS Next 3Y13.13%
EPS Next 5Y3.35%
Revenue 1Y (TTM)177.89%
Revenue growth 3Y-53.35%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-61.63%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y-5.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.37%
OCF growth 3YN/A
OCF growth 5YN/A